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Abstract
Rationale In Western societies, a considerable percentage 
of young people expose themselves to 3,4-methylenedioxy­
methamphetamine (MDMA or “ecstasy”). Commonly, 
ecstasy is used in combination with other substances, in 
particular alcohol (ethanol). MDMA induces both arousing 
as well as hallucinogenic effects, whereas ethanol is a 
general central nervous system depressant.
Objective The aim of the present study is to assess the acute 
effects of single and co-administration of MDMA and ethanol 
on executive, memory, psychomotor, visuomotor, visuospatial 
and attention function, as well as on subjective experience. 
Materials and methods We performed a four-way, double­
blind, randomised, crossover, placebo-controlled study in 
16 healthy volunteers (nine male, seven female) between 
the ages of 18-29. MDMA was given orally (100 mg) and 
blood alcohol concentration was maintained at 0.6%o by an 
ethanol infusion regime.
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Results Co-administration of MDMA and ethanol was well 
tolerated and did not show greater impairment of perfor­
mance compared to the single-drug conditions. Impaired 
memory function was consistently observed after all drug 
conditions, whereas impairment of psychomotor function 
and attention was less consistent across drug conditions. 
Conclusions Co-administration of MDMA and ethanol did 
not exacerbate the effects of either drug alone. Although the 
impairment of performance by all drug conditions was 
relatively moderate, all induced significant impairment of 
cognitive function.
Keywords MDMA. Ecstasy. Alcohol. Ethanol.
Interaction. Acute. Effects. Healthy volunteers. 
Neuropsychologic
Introduction
In Western societies, a considerable proportion of young 
people expose themselves to 3,4-methylenedioxymetham­
phetamine (MDMA or ‘ecstasy’; Gross 2002; Parrott 2001; 
Tancer and Johanson 2007). Ecstasy has gained widespread 
use in the ‘club’ scene, typically all-night parties with loud 
music and intense lights (Winstock et al. 2001). The 
average dose of ecstasy used recreationally is reported to 
be around 80-90 mg of MDMA with considerable 
individual variation (Tanner-Smith 2006). Ecstasy users 
are generally multidrug users who have experience with 
various recreational drugs and use these in combination 
with ecstasy (Gouzoulis-Mayfrank and Daumann 2006b). 
Probably due to its availability, alcohol remains one of the 
most co-used substances (Barrett et al. 2005). As the use of 
alcohol is known to induce impairment of cognitive 
function and decrease the awareness of this impairment,
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this can lead to dangerous behaviour like driving under 
influence (Lamers and Ramaekers 2001; Riley et al. 2001).
MDMA acts primarily by releasing serotonin (5- 
hydroxytryptamine (HT)) from pre-synaptic 5-HT termi­
nals. It reverses the direction of the reuptake transporter 
and increases 5-HT levels at the post-synaptic receptors 
(Liechti and Vollenweider 2000; Mlinar and Corradetti 
2003; Pifl et al. 1995). MDMA is also a potent releaser of 
dopamine and (nor)adrenaline (Colado et al. 2004; Liechti 
and Vollenweider 2001).
MDMA is rapidly absorbed following oral administra­
tion. Within 30 min, MDMA is detectable in the blood. 
Plasma levels peak at 1-2 h after drug administration, and 
maximum behavioural and subjective effects occur around 
1-2 h and have declined by 4 h in spite of persisting plasma 
levels (de la Torre et al. 2004; Green et al. 2003). Increasing 
the dose does not result in a proportional rise in plasma 
concentrations, which is indicative of non-linear pharma­
cokinetics (de la Torre et al. 2000).
The behavioural effects of MDMA resemble but are not 
restricted to effects of psychostimulants (e.g. amphetamines 
or ‘speed’) as well as hallucinogenics (e.g. lysergic acid or 
‘lysergic acid diethylamide’), although MDMA’s most 
characteristic effects are described as an increase in 
empathy and friendliness (Vollenweider et al. 2002). This 
led to MDMA being categorized as an ‘entactogen,’ as 
coined by Nichols and Oberlender (1990).
Most research into the cognitive effects of MDMA in 
humans has focused on the long-term effects, where only 
memory was consistently found to be impaired (Verbaten 
2003; Verkes et al. 2001). Our review of the acute effects 
of MDMA in humans showed that cognitive effects were 
assessed only in a limited number of studies, using diverse 
tests and generally addressing only certain aspects of 
neuropsychological function. As such, no consensus on 
MDMA’s cognitive effects could be reached (Dumont and 
Verkes 2006). Since then, reports on the effects of MDMA 
generally confirmed previous findings (Kuypers et al. 
2006; Kuypers et al. 2007; Ramaekers et al. 2006; Tancer 
and Johanson 2007). Interestingly, two studies reported 
effects of MDMA on memory, which had not been 
assessed previously. These reports showed acute impair­
ment of immediate and delayed recall of words as well as 
spatial memory by MDMA (Kuypers and Ramaekers 
2005, 2007).
Drinks containing ethanol, commonly referred to as 
alcohol, are widely available and regularly used in Western 
society. Ethanol is chiefly a central nervous system (CNS) 
depressant. It inhibits both excitatory and inhibitory post- 
synaptic potentials by potentiating the action of gamma- 
aminobutyric acid at its receptor (Suzdak et al. 1988). 
Reports of the cognitive effects of combined use of MDMA 
and ethanol in humans have been sparse in the literature.
Studies that were performed assessed psychomotor function, 
attentional performance and subjective effects (Hernandez- 
Lopez et al. 2002; Kuypers et al. 2006; Ramaekers et al.
2006). In general, MDMA and ethanol had no or opposite 
effects on effect measures, and as such co-administration 
did not exacerbate single-drug effects.
In the current study, we employed a series of tests 
sensitive to changes in all common neuropsychological 
domains induced by several pharmacological compounds, 
including amphetamines (Wezenberg et al. 2004).
It is generally acknowledged that the combined use of 
alcohol with other CNS-depressant drugs may enhance the 
effects of ethanol or of the other drugs. MDMA, however, 
has stimulant effects while ethanol is a sedative agent, 
suggesting that the effects of co-administration are dimin­
ished rather than augmented compared to the effects 
following single administration. This hypothesis was 
investigated during acute co-administration of MDMA 
and ethanol in healthy volunteers.
Materials and methods
Study design
This study utilised a four-way, double-blind, randomised, 
crossover, placebo-controlled design. Sixteen volunteers 
were randomly assigned to one of four treatment sequences. 
Each volunteer received a capsule containing either 100-mg 
MDMA or placebo and an ethanol-placebo infusion (target 
blood alcohol concentration (BAC) of 0.6%) with a 
washout of 7 days between each treatment.
Study outline
Subjects arrived in the morning and were admitted to the 
study after a negative urine drug screen (opiates, cocaine, 
benzodiazepines, amphetamines, methamphetamines and 
delta-9-tetrahydrocannabinol), as well as a negative alcohol 
breath test and recording of signs and symptoms of possible 
health problems. A light breakfast was offered. Drug 
administration was scheduled at 1030 hours and the alcohol 
infusion was started at 1100 hours for a duration of 3 h. At 
1130 hours, subjects performed the psychological test 
battery as described below. Specific test times are reported 
in Table 1. Subjects received lunch at 1400 hours and were 
sent home at 1700 hours after a medical check. Adverse 
events where recorded throughout the study day. Vital signs 
were monitored using a Datascope® Accutorr Plus™ 
cardiovascular monitor and Braun® type 6021 ThermoScan 
during the study day. The data presented in this report are a 
subset of a larger data set, which will be reported 
elsewhere.
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Table 1 Timeline
Neuropsychological tests Description
Drug administration 
18-word list immediate recall 
SDST 
SDRT 
Pursuit task 
Tangles task 
Switch task
18-word list delayed recall 
18-word list delayed recognition 
Point task
Visual analogue scales 
Times are relative to drug administration.
Subjects
Sixteen healthy volunteers (nine male, seven female), 
regular users of ecstasy and alcohol, aged 18-29 years 
and within 80-130% of their ideal bodyweight, were 
recruited through advertisement on the internet and at local 
drug testing services. They were all in good physical and 
mental health as determined by assessment of medical 
history, a medical, electrocardiogramme and clinical, 
haematological and chemical blood examination. Previous 
drug use was assessed using a structured interview. Fifteen 
volunteers were right handed and one was left handed. The 
study was approved by the local Medical Ethics Commit­
tee. All subjects gave their written informed consent before 
participating in the study and were compensated for their 
participation. Subject demographics and drug history are 
reported in Table 2.
Table 2 Volunteer demographics-drug history
Mean SD Min Max
Age (years) 22.1 2.9 18.0 29.0
Education (years) 16.5 1.6 12 18
Height (cm) 174.7 12.3 147.0 189.1
Weight (kg) 67.5 12.4 45.7 88.4
Opiates 0.1 0.3 0 1
LSD 2.5 6.6 0 25
Amphetamines 37.3 81.1 0 250
Ecstasy 94.6 138.4 14 431
Cannabis 1,174.3 1,665.5 20 5,840
Cocaine 33.7 105.7 0 400
Alcohol 2,367.9 1,981.6 50 5,200
Solvents 3.6 13.3 0 50
Barbiturates 0 0 0 0
Benzodiazepines 18.6 57.3 0 216
Psilocybin 6.9 10.4 0 30
Drug quantities mentioned are lifetime drug exposures, not further 
specified.
Time (h:m)
0:00
1:00
1:05
1:08
1:10
1:13
1:17
1:22
1:23
1:25
1:30
One subject had a mild adverse reaction (local vascular 
reaction) to the alcohol infusion and one subject did not 
refrain from drug use; both (one male, one female) were 
excluded from further participation and results obtained 
were not included in the data analysis.
Drugs and dosages
MDMA (or matched placebo) was given as a capsule in a 
single dose of 100 mg via oral administration (dose range; 
1.1-2.2 mg/kg). MDMA was obtained from Lipomed AG, 
Arlesheim, Switzerland and encapsuled according to Good 
Manufacturing Practise by the Department of Clinical 
Pharmacy, UMC St Radboud, Nijmegen, the Netherlands. 
MDMA 100 mg orally is a relevant dose in the range of 
normal single recreational dosages. Previous experiments in 
humans used doses up to 150 mg without serious adverse 
events. Ethanol (or matched placebo) was administered 
continuously by intravenous infusion of 10% ethanol in 
glucose solution resulting in an ethanol blood concentration 
of 0.6% with a duration of 3 h as described below.
Alcohol clamping
To standardise alcohol delivery and maintain a constant 
alcohol blood concentration over time, an intravenous 
ethanol clamp was used. Ethanol was administered by 
infusion of a 10% ethanol in glucose solution for a duration 
of 3 h. The infusion rate was calculated using frequent 
breath alcohol concentrations measurements, according to a 
previously designed algorithm (Amatsaleh et al. 2006a). 
Breath alcohol concentration was assessed using a HONAC 
AlcoSensor IV® Intoximetre.
An intravenous administration route was chosen, 
ensuring standardisation of the rate and bioequivalence 
of ethanol administration. This is an important pre­
requisite for predictable pharmacokinetics of ethanol. 
The process was semi-automated using a computer
Immediate recall of 18-word list
Translate symbols to digits with key present in 90 s
Translate symbols to digits from memory
Keep dot within moving circle
Tangled line leads to which target?
Follow, possibly conflicting, instructions (choice between left or right) 
Delayed recall of 18-word list
Recognise words of 18-word list memorised earlier among 18 distracters 
Keep pen steady in air, measures tremor 
16 100-mm scales for subjective experiences
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spreadsheet programme, which uses measured breath 
alcohol concentrations to calculate the infusion rate 
needed to maintain the ethanol level at 0.6 mg/mL. This 
is a relevant dose equivalent to peak levels of approx­
imately two to three units of alcoholic beverages. In 
many European countries driving is prohibited at BAC 
above 0.5%. This limit has been confirmed by a report 
that shows that at an average BAC of 0.6% psychomotor 
performance is significantly impaired (Amatsaleh et al. 
2006b). A BAC of 0.6% is equivalent to approximately 
two to three alcoholic beverages commonly used in social 
settings in Western society, which is considered to be a 
safe and relatively moderate dose, despite its significant 
CNS effects.
MDMA blood analysis
For the assessment of serum levels of MDMA, blood 
samples were collected 90 min after drug administration 
from each subject on each study day. Venous blood samples 
(10 ml) were collected into heparinised tubes, centrifuged 
immediately at 4°C for 15 min. Plasma was split into 
aliquots of 2 mL (to prevent over-freezing-thawing), frozen 
rapidly using liquid nitrogen and stored at -80°C. Samples 
were analysed for MDMA and MDA concentration by the 
Toxicology unit of the Leyenburg hospital, The Hague, the 
Netherlands.
Neuropsychological tests, apparatus and procedure
The performance on all neuropsychological tests was 
recorded by means of a digitising tablet (WACOM UD- 
1218-RE), a laptop computer, a pressure-sensitive pen 
(which could also be used as a cursor) and test forms. 
The x and y coordinates of the pen tip on and up to 5 mm 
above the digitiser were sampled with a frequency of 
200 Hz and a spatial accuracy of 0.2 mm. The time 
schedule of the tests is summarised in Table 1.
To familiarise the subjects with the tests and procedures, 
they were invited to the hospital to perform a practise 
session within 1 week before the actual study days. All tests 
had five equivalent versions for four test days and one 
practise day, test versions were counterbalanced over test 
days.
Executive function
Switch task This test is a reaction time task measuring 
simple as well as complex reaction time, assessing 
executive performance (Baker and Letz 1986). After a 
random period of 0.75 to 1.75 s, two rectangular fields 
appeared on both sides of a circle in the centre of the
screen. Only one of the two fields provided the subjects 
with information, either a colour, an arrow or both. The 
other non-informative field always had a neutral grey 
colour. Five conditions were subsequently presented to 
subjects. If only green fields appeared, subjects had to 
move as fast as possible into the green field. If green and 
red fields appeared, subjects had to move into the green 
field and away from the red field as soon as they 
appeared.
If green fields with a left or right arrow were presented, 
subjects were to move into the direction of the arrow. Green 
and red fields with a left or right arrow indicated that 
subjects were to follow the direction of the arrows in the 
green field, but the opposite direction of the arrows in the 
red field. Finally, the first condition was repeated. All 
conditions contained 20 trials except condition four in 
which there were 40 trials (total=120 trials). The outcome 
measures were the mean reaction times per condition. The 
last condition is a repetition of the first to check for possible 
changes in attention.
Memory
Eighteen-word list A verbal memory test based on the 
classic Auditory Verbal Learning Test (Vakil and Blachstein 
1993) was used. A variant was made consisting of a list of 
18 words. The classic test uses 15 words. A longer wordlist 
was chosen, however, to prevent ceiling effects. The list 
was presented verbally three times. Under normal circum­
stances, subjects are supposed to remember an increasing 
number of words after each trial. Directly after each 
presentation, and after an interval of 20 min, subjects were 
asked to recall as many words as possible. After the delayed 
recall trial, a list of 36 words was presented from which 
they were asked to recognise the 18 words previously 
presented. The incorrect words were distracters and 
resembled the correct words in a semantic or phonologic 
manner. Responses were either correct positive (when a 
word that was recognised was indeed part of the list 
presented during immediate recall) or false positive (when a 
word was recognised but was not part of the list presented 
during immediate recall, e.g. the word was a distracter). 
The outcome measure was the number of correctly recalled 
or recognised words for the average of the three immediate 
recall trials, the delayed recall trial and the delayed 
recognition trial.
Symbol digit recall test The symbol digit recall test 
(SDRT) followed directly after the Symbol Digit Substi­
tution test (SDST), which is discussed in the last 
paragraph of this section. After subjects had finished 
the SDST, they were shown the symbols of the SDST
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without the translation key, one at a time, and asked to 
produce the corresponding numbers. This test is based on 
an extended procedure of the SDST to measure inciden­
tal learning (Kaplan et al. 1991). The outcome measure 
was the number of correctly translated symbols.
Psychomotor function
Pursuit task To measure implicit procedural learning, a 
computerised version of the rotor pursuit task was used. 
This test is based on the classic rotary pursuit task 
(Ammons 1951). It is a continuous motor task. Subjects 
had to follow the movement of a large target stimulus on 
the computer screen with a cursor by moving the pen over 
the XY tablet. The speed of the target gradually increased 
when the cursor was contained within the target but 
decreased considerably when it was not. The target 
followed a spatially predictable circular path over the 
screen. The outcome measure for this test was the total 
number of rotations within 2 min.
Point task The point task, a measure for tremor, required 
subjects to try to keep the cursor inside a very small circle 
for 1 min, while avoiding contact between the pen and the 
test form. The outcome measure for this test was the 
deviation from the target.
Visuospatial and visuomotor function
Tangle task The tangle task required the subject to 
visually track a particular line winding through two to 
four other lines. On subsequent trials, the tangles 
increased in complexity; they got longer and made more 
90° turns. The paper form had a start area and five target 
areas, numbered 1 to 5, which reflect the maximum 
target areas on the screen, starting with only three target 
areas.
This test is modelled after the visualisation test from 
the ‘kit for factor referenced cognitive tests.’ It was 
selected by the US NAVY to study environmental and 
other time-course effects and has good task stability and 
reliability (Bittner et al. 1986). The outcome measures 
are the reaction time per trial and the number of correct trials 
in 2 min.
Attention
Symbol Digit Substitution test This test is a version of the 
subtest from the Wechsler Adult Intelligence Scale 
(Wechsler 1981). Subjects had to substitute the nine
symbols for the digits 1 -9 on the basis of a given 
translation key. The outcome measure was the total 
number of digits completed in 90 s.
According to Hege et al. (1997) this task measures 
many cognitive components, e.g. visuospatial scanning, 
intermediate memory, perceptual motor speed and speed 
of cognitive processing. Therefore, subsequent analyses 
were performed in order to attempt and disentangle these 
cognitive processes. Based on pen pressure, movement 
trajectories were defined as either pen-up periods or pen- 
down periods. This allowed for subsequent analysis of 
matching times and movement (writing) times in the 
Symbol Digit Substitution test. For the motor component, 
the mean writing times were computed. For the more 
cognitive component, the mean matching times were 
computed. These analyses have been previously per­
formed (Sabbe et al. 1999; Wezenberg et al. 2005).
Subjective
Subjective effects were recorded using the Bond and 
Lader (Visual Analogue) Mood Rating Scale (BLMRS). 
This inventory was completed at the end of each 
neuropsychological test battery on each study day.
The BLMRS scale consisted of 16 lines, each 10 cm 
in length, with opposite terms at each end of the line 
(alert-drowsy, calm-excited, strong-feeble, muzzy-clear­
headed, well coordinated-clumsy, lethargic-energetic, 
contented-discontented, troubled-tranquil, mentally 
slow-quick witted, tense-relaxed, attentive-dreamy, 
incompetent-proficient, happy-sad, antagonistic-amicable, 
interested-bored, withdrawn-gregarious). Subjects were 
asked to indicate which item was more appropriate by 
marking the line. The outcome measure was the distance to 
the marker on each scale. These scale scores were then 
aggregated to scores for ‘calmness,’ ‘alertness’ and ‘con­
tentedness’ as described by Bond et al. (1974).
Statistical analyses
Statistical evaluation (using SPSS 11.5 for Windows) 
was performed with general linear model repeated- 
measures analysis of variance. Main and interaction 
effects were tested using a two-factor (‘ethanol’ and 
‘MDMA’), two-level (absent versus present) multivariate 
model.
The analysis of the data was based on Maxwell and 
Delaney (2004) and Kirk (1995). First the presence of 
interaction (non-additivity) was tested with alfa=0.05. 
When the interaction was not statistically significant we 
proceeded by testing the main effects, each at alfa=0.05. In 
the case of a significant interaction, we proceeded by
Ö  Springer
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testing simple main effects of each drug, i.e. MDMA vs. 
placebo and ethanol vs. placebo.
Results
Subject demographics are summarised in Table 2. Out of 
16 subjects, 14 completed the study procedure. One 
subject had a mild adverse reaction (local vascular 
reaction which subsided with infusion stop) to the alcohol 
infusion and one subject did not refrain from drug use; 
both were discontinued from study participance and data 
already obtained were not included in statistical analysis. 
Only significant results are mentioned in this section, 
unless stated otherwise.
MDMA blood concentration 90 min after administration 
did not differ for MDMA single vs. MDMA and ethanol 
co-administration and was on average 196 ^g/L (SD= 
83 |ag/L). Blood alcohol concentration was maintained at 
an average of 0.54% (SD=0.07%).
Executive function
Executive function (switch task) did not show any 
significant main or interaction effects.
Delayed recall as assessed by the 18-word list was 
impaired by MDMA (F(1, 12)= 10.447, p =0.007) as well 
as by ethanol (F(1, 12)= 16.031, p =0.002). The SDRT, also 
a test for delayed recall, showed a similar pattern of 
impairment by MDMA (F(1, 12)=5.300, p =0.038) as well 
as by ethanol (F(1, 12)=7.654, p =0.016).
Psychomotor function
Psychomotor function was assessed with tests for tremor 
(point task), accuracy (pursuit task) and speed (SDST motor 
time, see Fig. 2); other SDST results are reported in the 
section “Attention.” Ethanol impaired psychomotor speed 
as reflected in the increase in SDST motor time (F(1, 12)= 
9.295, p =0.009).
Visuospatial and visuomotor function
Visuospatial and visuomotor function were measured with 
the tangle task, subdivided into ‘total number correctly 
solved’ and ‘reaction time,’ and did not show any 
significant effects, although a trend of impairment by 
MDMA (F(1, 12)=3.966, p =0.068) was observed.
Attention
Memory function
Memory function was assessed by the 18-word list 
(outcome measures were ‘immediate recall,’ ‘delayed 
recall’ and ‘recognition,’ see Fig. 1) as well as the SDRT. 
Immediate recall was impaired only by ethanol (F(1, 12)= 
8.71, p =0.011).
Attention was assessed with the SDST task; the outcome 
measures were ‘motor time’ (see “Psychomotor function”), 
‘matching time’ (Fig. 3) and ‘total number correctly 
substituted.’ The time required to match symbols to the 
corresponding numbers showed a significant MDMA and 
ethanol interaction (F(1, 12)=6.214, p =0.027). Tests for 
simple main effects revealed that both single-drug con­
ditions reduced attention compared to placebo (ethanol
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Fig. 1 Memory effects (18-word list), Immediate: immediate recall, 
average score of three trials of correctly recalled verbally presented 
words, Delayed: correctly recalled verbally presented words 20 min 
after presentation, Recognition: correctly recognised verbally pre­
sented words containing 18 distracters, 20 min after presentation 
(mean and SEM). Immediate recall was impaired only by ethanol 
(F(1, 12)=8.71, p =0.011). Delayed recall was impaired by MDMA 
(f(1, 12)=10.447, p =0.007) as well as by ethanol (F(1, 12)=16.031, 
p =0.002); recognition was not affected by any drug condition
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Fig. 2 Psychomotor effects: SDST writing time (mean, SEM). 
Ethanol increased writing times (F(1, 12)=9.295, p =0.009)
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1250 -,
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□  placebo m ethanol m MDMA ■  MDMA+ethanol
Fig. 3 Attention effects: SDST matching time, i.e. time needed for 
translation (mean and SEM). A significant MDMA by ethanol 
interaction was found (F(1, 12)=6.214, p =0.027)
F(1, 13)=6.248, p =0.027; MDMA F(1, 13)=6.822, p = 
0.022; see Fig. 3).
Subjective effects
Subjective effects are depicted in Fig. 4. Feelings of 
‘contentedness’ where increased significantly by MDMA 
only (F(1, 12)=4.710, p =0.049).
A significant interaction effect (F(1, 12)=7.358, p = 
0.018) was found for feelings of ‘alertness.’ Tests for 
simple main effects revealed that ethanol but not MDMA 
significantly decreased feelings of alertness compared to 
placebo (F(1, 13)=50.613, p <0.001). Feelings of ‘calm­
ness’ were reduced only by MDMA (F(1, 12)=20.259, 
p =0.001).
10
Contentedness Alertness Calmness
_ placebo v ethanol n  MDMA ■ MDMA+ethanol 
Fig. 4 Subjective effects (aggregated Bond and Lader scores, mean 
and SEM). Feelings of ‘Contentedness’ where increased signifi­
cantly by MDMA only (F(1, 12)=4.710, p =0.049) A significant 
interaction effect (F(1, 12)=7.358, p =0.018) was found for feelings 
of ‘Alertness.’ Feelings of ‘Calmness’ were reduced only by MDMA 
(F(1, 12)=20.259, p =0.001)
Discussion
This study demonstrates that the effects of 100-mg MDMA, 
commonly known as ecstasy, on cognitive function are no 
greater than the effects of a relatively low dose of ethanol. 
This is remarkable as these results suggest that the effects 
of 100-mg MDMA are comparable to the peak effects of 
two to three alcoholic beverages. Co-administration of 
these compounds did not result in any significant cognitive 
impairments beyond those observed after administration of 
only ethanol. The use of moderate amounts of alcohol is 
common in Western societies and, although impairing 
cognitive function, socially accepted, while ecstasy use 
remains very controversial. Of course, our findings only 
relate to the acute neuropsychological implications of 
ecstasy use and not to the physiological and long-term 
effects, which rightfully remain topics of discussion 
(Gouzoulis-Mayfrank and Daumann 2006a; Nutt 2006; 
Parrott 2007).
Drug effects observed in this placebo-controlled cross­
over study were moderate. Co-administration was well 
tolerated as indicated by the subjective scores, which were 
comparable to those found after single administration of 
MDMA. An interaction of MDMA and ethanol was found 
for subjective alertness scores. Ethanol, as expected, 
reduced subjective alertness, while MDMA co-administration 
reversed the reduction of subjective alertness by ethanol. In 
the present study, MDMA by itself did not significantly 
affect subjective alertness, although this effect has been 
consistently reported in other studies and is a well-known 
effect of amphetamines. However, MDMA did significantly 
reduce subjective calmness, i.e. subjects felt more excited 
after MDMA use. Probably, the Bond and Lader Mood 
Rating Scale is not well suited for the assessment of 
subjective effects of psychoactive drug effects and future 
studies should employ more appropriate subjective drug 
effect measures such as the Profile Of Mood States (de Wit 
et al. 2002).
When considering the results for each neuropsycholog­
ical domain, executive function was not affected by any 
drug condition. A previous study showed impairment of 
executive function by ethanol but not MDMA, although 
ethanol impaired performance in only one out of three tests 
of executive function (Lamers et al. 2003). The BAC in this 
study was 0.3% at the time of testing compared to 0.56% 
in our current study, suggesting a lack of sensitivity of the 
test employed in the current study.
The above-mentioned previous study also reported 
visuospatial and visuomotor impairment by MDMA but 
not by ethanol. Although not significant, our current results 
show a similar pattern where MDMA showed a trend of 
impairment of visuospatial and visuomotor function, 
whereas ethanol did not.
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Psychomotor function was impaired only after ethanol 
administration (SDST motor time, see Fig. 2). The majority 
of studies addressed in our review of acute effects of 
MDMA in humans (Dumont and Verkes 2006) did not 
report any change in psychomotor function after MDMA 
either. However, increased psychomotor function after 
MDMA has also been found (Lamers et al. 2003; 
Ramaekers et al. 2006). These studies administered 75 mg 
instead of 100 mg. Possibly, the effects of MDMA are 
biphasic, with a low dose of MDMA exhibiting more 
amphetamine-like effects, e.g. arousal, increasing perfor­
mance, whereas higher doses may elicit more hallucino­
genic effects and impair performance (Liechti et al. 2001; 
Solowij et al. 1992).
As mentioned above, MDMA co-administration re­
versed the ethanol-induced feelings of sedation, although 
MDMA was unable to reverse the psychomotor impair­
ment induced by ethanol. This dissociation between 
subjective and objective sedation confirms previous find­
ings by Hernandez-Lopez et al. (2002).
Several studies assessed MDMA’s effect on attention 
using the Digit Symbol Substitution Task (DSST), although 
no significant effects were found (Cami et al. 2000; Farre et 
al. 2004; Kuypers and Ramaekers 2005). One study 
reported decreased DSST performance after ethanol as well 
as after ethanol and MDMA co-administration but no effect 
of MDMA (Hernandez-Lopez et al. 2002). Our findings 
confirm these findings to a large extent. We found no main 
effects of MDMA or ethanol on attention, although an 
interaction of ethanol and MDMA for ‘matching time’ 
(time required to match the number to the corresponding 
symbol) was found. Co-administration of MDMA and 
ethanol increased ‘matching time’ comparable to the 
increase observed after both MDMA and ethanol single 
administration, compliant with our hypothesis of competi­
tive mechanisms of action of both drugs (see Fig. 3).
Studies investigating the long-term effects of MDMA 
consistently found memory to be affected (Verbaten 2003). 
In the present report, almost all memory measures showed 
quantitatively comparable impairment for each drug condi­
tion (see Fig. 1), although the effect of MDMA on 
immediate recall did not reach statistical significance. Only 
delayed recognition was not impaired in any drug condi­
tion. These findings suggest a deficit in the retrieval of 
verbal information encoded in memory, rather than impair­
ment in the storage of information. Our findings are similar 
to the results of a previous study on MDMA-induced 
effects on memory (Kuypers and Ramaekers 2005). In this 
previous study, no memory impairment was observed after 
methylphenidate administration, a pronounced dopamine 
and norepinephrine releaser, suggesting the involvement of 
serotonin in memory impairment. Several other studies also 
have shown serotonin-mediated modulation of memory
function through interaction with the cholinergic neuro­
transmitter system, although the details of this complicated 
interaction remain elusive (Cassel and Jeltsch 1995; Garcia- 
Alloza et al. 2006; Meneses 2007). Generally, subjects 
stated that they were well aware of their impaired memory 
after MDMA.
BAC was on average 0.56%. At this level, driving is 
prohibited by law in many European countries because of 
its interference with normal functioning. Although the 
effects were moderate, ethanol impaired cognitive perfor­
mance in various tests. Similar moderate effects were 
observed with MDMA 100 mg, considered to be slightly 
above the average recreational dose (Tanner-Smith 2006). 
This might be considered surprising for a drug with 
reported robust subjective stimulating and hallucinogenic 
properties. However, because the effects caused by a single 
dose of 100-mg MDMA were comparable to the effects of a 
BAC of 0.56%, this dose should by inference be 
considered unacceptable in motorised traffic.
Arguably, the moderate drug effects as found in this 
study could be explained by ‘ missing’ the time of the 
maximal drug effects. Although the average MDMA blood 
concentration reported here (196 H-g/L) is comparable to 
Cmax of 100-mg MDMA (199.8 H-g/L) as reported by de la 
Torre et al. (2000), MDMA concentration was assessed at 
the end of the testing procedure. However, Hernandez- 
Lopez et al. (2002) found significant effects at 60 min as 
well as 90 min after drug administration, arguing against 
the suggestion of ‘missing’ peak drug effects.
The circumstances in which these substances are 
normally used cannot be fully recreated in the laboratory 
and this may have suppressed the effects of both sub­
stances. It is not unlikely that these substances show 
enhanced effects when tested under typical circumstances 
and surroundings. Recently, Parrott et al. (2006) concluded 
that the increase in physical activity and body temperature 
typically experienced when using MDMA enhance MDMA 
effects. Ball et al. (2006) demonstrated that a familiar 
surrounding increased MDMA-induced locomotor response 
as well as single-neuron activity in rats, compared to 
unfamiliar surroundings. Therefore, the psychosocial con­
text in which MDMA is used, along with the different 
expectations and behaviour, probably influences its effects 
(Sumnall et al. 2006). It is unlikely, however, that this 
affects the quality of the interactions of MDMA and 
ethanol.
In conclusion, co-administration of MDMA and ethanol 
did not impair cognitive function significantly more than 
MDMA or ethanol administration alone. The most prom­
inent effect of (co-)administration of MDMA and ethanol 
was an impairment of memory. Ethanol also impaired 
psychomotor function. Although the impairment of perfor­
mance by each drug condition was relatively moderate, this
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significant impairment of cognitive function should be 
considered intolerable in motorised traffic and other 
cognitively demanding situations as confirmed by previous 
research and as defined by law. However, the effects of 
these drugs in the concentrations used in the present study 
on established neuropsychological tests appear to be 
smaller than one would assume based on their reputation.
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